Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022.  

New data from pooled analysis shows DecisionDx®-Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk (T1, ≤1mm) by traditional staging systems

  • Survey of 400 dermatologic clinicians demonstrates how DecisionDx®-SCC results can lead to risk-aligned treatment plan changes for patients with high-risk squamous cell carcinoma
  • Castle’s laboratory workflow for MyPath® Melanoma and DecisionDx® DiffDx®-Melanoma increased the reporting of clinically actionable results to over 99% in a performance cohort of 350 archival biopsy samples

Continue reading

Gene Variation May Be Early Indicator for Gastric Cancer

A new study identified a gene variation that could inform clinicians which patients are more susceptible to developing stomach cancer. Researchers at the University of Arizona Health Sciences are hoping to catch stomach cancer before it develops in at-risk patients. In a paper published in Gastroenterology, researchers identified a genetic variation that could help identify when patients with Helicobacter pylori are more likely to develop stomach cancer.Continue reading

Exact Sciences Showcases Breadth Of Early Detection And Treatment Guidance Portfolio With Multiple Data Presentations At ASCO 2022

Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, showcased  new data supporting its cancer tests and treatment guidance tools  in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,  held June 3-7 in Chicago, Illinois.Continue reading

Humabiologics and REGEMAT 3D partner to provide printable human-derived biomaterials to the European Market

Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and REGEMAT 3D, a company at the forefront of personalized biofabrication solutions, announce they have entered into a non-exclusive distribution agreement to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European bioprinting and drug testing market.Continue reading